Last: | $99.60 |
---|---|
Change Percent: | -0.59% |
Open: | $99.65 |
Close: | $99.60 |
High: | $99.78 |
Low: | $99.26 |
Volume: | 1,119,054 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$99.6 | $99.65 | $99.6 | $99.78 | $99.26 | 1,119,054 | 05-08-2024 |
$99.07 | $98.6 | $99.07 | $99.19 | $98.54 | 1,159,818 | 05-07-2024 |
$97.73 | $97.5 | $97.73 | $97.83 | $97.11 | 1,180,808 | 05-06-2024 |
$97.27 | $97.75 | $97.27 | $97.91 | $97.07 | 1,045,674 | 05-03-2024 |
$97.34 | $97.21 | $97.34 | $97.47 | $96.85 | 1,426,052 | 05-02-2024 |
$97.5 | $96.97 | $97.5 | $97.87 | $96.715 | 1,284,177 | 05-01-2024 |
$97.13 | $97.08 | $97.13 | $97.82 | $96.92 | 1,359,879 | 04-30-2024 |
$97.09 | $97.76 | $97.09 | $97.91 | $96.86 | 2,144,384 | 04-29-2024 |
$97.44 | $97.76 | $97.44 | $98.22 | $97.44 | 1,562,845 | 04-26-2024 |
$99.06 | $98.63 | $99.06 | $99.24 | $98.26 | 2,338,494 | 04-25-2024 |
$98.35 | $98.5 | $98.35 | $98.55 | $97.405 | 2,233,162 | 04-24-2024 |
$97.28 | $98.74 | $97.28 | $99.5 | $97.0305 | 3,837,430 | 04-23-2024 |
$95.12 | $94.76 | $95.12 | $96.03 | $94.72 | 2,447,775 | 04-22-2024 |
$94.36 | $93.2 | $94.36 | $94.495 | $93.15 | 2,338,264 | 04-19-2024 |
$92.57 | $92.85 | $92.57 | $92.93 | $92.35 | 1,054,610 | 04-18-2024 |
$93.08 | $93.63 | $93.08 | $93.78 | $92.87 | 1,168,714 | 04-17-2024 |
$93.2 | $92.85 | $93.2 | $93.37 | $92.64 | 1,914,845 | 04-16-2024 |
$94.41 | $94.2 | $94.41 | $94.965 | $94.11 | 1,501,028 | 04-15-2024 |
$93.52 | $94.99 | $93.52 | $95.05 | $93.41 | 2,099,603 | 04-12-2024 |
$94.34 | $94.87 | $94.34 | $94.91 | $93.75 | 1,623,290 | 04-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
Researchers at Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (...
2024-05-08 12:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...